Earnings release
Page 1
EARNINGS RELEASE 3Q | 2025 November,09,2025
Page 2
EARNINGS RELEASE November,09,2025 Belo Horizonte, November 09th, 2025 Rede Mater Dei de Saúde ('Mater Dei' or 'Company') (B3: MATD3) announces its results for the third quarter of 2025 (3Q25). Figures are presented on a consolidated basis in millions of Reais, except where otherwise specified. Comparisons are referenced against the third quarter of 2024 (YoY comparisons) and the second quarter of 2025 (QoQ comparisons). The quarterly information complies with Brazilian and international accounting rules (IFRS) and has been reviewed by independent auditors. For comparability purposes, the 2024 results do not consider the figures for Porto Dias, except for financial covenant purposes. 2 Consolidated values Financial Indicator (BRL Million) 3Q25 3Q24 ∆ 2Q25 ∆ Operational Beds (average of the period) 1,246 1,251 (0.4%) 1,231 1.2% Patients-day (total of the period) 87,473 83,436 4.8% 87,369 0.1% Occupancy rate (average of the period) 76.3% 72.5% 3.8pp 78.0% (1.7pp) Occupancy rate day patient (average of the period) 81.7% 77.0% 4.7pp 83.0% (1.3pp) Average Ticket (BRL mm / bed) 2.67 2.41 10.9% 2.55 4.4% Net Revenue 568 488 16.3% 546 4.0% Gross Profit 171 140 22.1% 165 3.8% Adjusted EBITDA 126 91 38.7% 115 9.3% EBITDA Margin 22.2% 18.6% 3.6pp 21.1% 1.1pp Cash and equivalents (excl. buybacks and dividend) 775 756 2.6% 720 7.7% Net Debt (excl. buybacks and dividend) 642 710 (9.6%) 690 (6.9%) Net Debt (excl. buybacks and dividend)/EBITDA LTM 1.5x 1.3x 0.2x 1.4x 0.1x Trimestral Year to Date Financial Indicator (BRL Million) 9M25 9M24 ∆ Operational Beds (average of the period) 1,215 1,247 (2.6%) Patients-day (total of the period) 252,655 256,767 (1.6%) Occupancy rate (average of the period) 76.2% 75.2% 1.0pp Occupancy rate day patient (average of the period) 81.5% 79.8% 1.7pp Average Ticket (BRL mm / bed) 2.62 2.34 11.7% Net Revenue 1,613 1,465 10.1% Gross Profit 480 437 9.7% Adjusted EBITDA 338 287 17.6% EBITDA Margin 20.9% 19.6% 1.3pp
Page 3
EARNINGS RELEASE November,09,2025 Highlights 3 Operational and Financial Consolidated ✓ Record Net Revenue and EBITDA in 3Q25 and 9M25 ✓ Record-High operating cash generation in a single quarter ✓ Net Debt reduction of BRL 59 million vs 2Q25 (QoQ) and BRL 79 million vs. 3Q24 (YoY), excluding share buybacks, cash outflows related to the debt Exchange transaction, and dividend payments during the period. RMBH: ✓ 4% Net Revenue growth vs. 2Q25 (QoQ) and 13% vs. 3Q24 (YoY), reaching a record-high in the RMBH (Belo Horizonte Metropolitan Region). ✓ 5% growth in oncology patients and 6% growth in surgical procedures scheduled vs. 2Q25 (QoQ ✓ Nova Lima unit: 23% Net Revenue growth vs. 2Q25 (QoQ), with a 12% increase in surgical procedures scheduled and standout operational performance in oncology, driven by the new reference team. Salvador: ✓ Record-High Net Revenue and EBITDA margin expansion vs. 2Q25 (QoQ). ✓ 27% Net Revenue growth vs. 3Q24 (YoY), driven by a 59% increase in oncology patients and a 24% increase in surgical procedures scheduled. Acquired Units: ✓ Record-High Net Revenue and EBITDA in 3Q25. ✓ 16% growth in oncology patients and 8% growth in surgical procedures scheduled vs. 2Q25 (QoQ). ✓ Uberlândia unit delivered its highest-ever (or all-time high) quarterly Net Revenue and EBITDA. ❑ Mater Dei Santo Agostinho unit recognized at CONAHP, obtaining the QGA seal following an indicator validation program. This seal acknowledges the quality and reliability of data reported to ANAHP, ensuring transparency and market recognition. ❑ Highest Network-wide monthly NPS (Net Promoter Score) recorded in October 2025 and highest quarterly NPS in 3Q25, with standout performance from the RMBH and Uberlândia HUBs. ❑ New Da Vinci Robot at the Nova Lima unit. ❑ New Robot for orthopedic surgery at the Uberlândia unit. ❑ In Salvador, the first robotic-assisted cardiac surgery performed in a hospital in the North and Northeast regions of Brazil. Awards and Hospital Quality Indicators CAR-T Cell Therapy ❑ Introduction of CAR-T Cell Therapy at the Contorno Hospital. This therapy represents a revolution in hematology-oncology treatment. It is a form of personalized immunotherapy in which the patient's own T-lymphocytes are collected and genetically modified to act more efficiently within the patient's immune system. Robotic-Assisted Surgery Highlights
Page 4
EARNINGS RELEASE November,09,2025 Destaques do Trimestre Revenues Volume 4 1. Figures do not include those from Porto Dias Hospital 1,251 1,187 1,166 1,231 1,246 72.5% 71.7% 74.2% 78.0% 76.3% 77.0% 77.0% 79.7% 83.0% 81.7% 3Q24 4Q24 1Q25 2Q25 3Q25 Evolution of Average Operational Beds and Occupancy Rate¹ Operational Beds Occupancy Rate Occupancy Rate ( + Day Hospital Patients) 83,436 78,350 77,813 87,369 87,473 6,572 6,988 7,201 6,980 7,289 3Q24 4Q24 1Q25 2Q25 3Q25 Número de pacientes-dia e Ticket Médio (R$/paciente-dia) Nº de Paciente-dia Ticket Médio (R$)
Page 5
EARNINGS RELEASE November,09,2025 Destaques do Trimestre BRL Millions Consolidated 3Q25 3Q24 ∆ 3Q25 2Q25 ∆ 3Q25 9M25 9M24 ∆ 9M25 Healthcare Plans 591.5 503.9 17.4% 565.2 4.6% 1,674.0 1,511.4 10.8% Private Patients 36.9 35.8 3.1% 35.6 3.6% 106.3 107.5 -1.1% Other Revenues 9.2 8.7 5.2% 9.0 1.7% 27.5 25.9 6.1% Gross Revenue 637.6 548.4 16.3% 609.9 4.5% 1,807.8 1,644.8 9.9% Disallowances (27.8) (23.7) 17.2% (26.5) 4.6% (78.6) (71.0) 10.6% Taxes and Deductions (42.0) (36.2) 15.9% (37.5) 11.8% (116.2) (108.5) 7.1% Net Revenue 567.9 488.5 16.3% 545.8 4.0% 1,613.0 1,465.3 10.1% Revenues Average Ticket and Consolidated Figures 5 1. Figures do not include those from Porto Dias Hospital 2.41 2.56 2.64 2.55 2.67 3Q24 4Q24 1Q25 2Q25 3Q25 Average Ticket (BRL Mm / bed)¹ +4.4% +10.9%
Page 6
EARNINGS RELEASE November,09,2025 Destaques do Trimestre Costs Cost of Services Provided BRL Millions Consolidated 3Q25 3Q24 ∆ 3Q25 2Q25 ∆ 3Q25 9M25 9M24 ∆ 9M25 Materials and medicines -154.8 -128.2 20.7% -147.2 5.2% -431.7 -390 10.7% % of net revenue 27.3% 26.2% 1.1pp 27,00% 0.3pp 26.8% 26.6% 0.2pp Personnel -110.9 -103.9 6.7% -106.2 4.4% -321.3 -297.2 8.1% % of net revenue 19.5% 21.3% (1.8pp) 19.5% - 19.9% 20.3% (0.4pp) Medical service fees -59.7 -55.1 8.3% -57.4 4.0% -172.2 -155.1 11,00% % of net revenue 10.5% 11.3% (0.8pp) 10.5% - 10.7% 10.6% 0.1pp Maintenance and upkeep -23.1 -20.2 14.2% -22.9 0.7% -67.6 -61.7 9.5% % of net revenue 4.1% 4.1% - 4.2% (0.1pp) 4.2% 4.2% - Depreciation and amortization -22.4 -18.7 19.9% -22 2,00% -66.4 -55.2 20.4% % of net revenue 3.9% 3.8% 0.1pp 4,00% (0.1pp) 4.1% 3.8% 0.3pp Other costs -25.8 -22.2 16.3% -25.3 2.3% -74 -68.7 7.8% % of net revenue 4.5% 4.5% - 4.6% (0.1pp) 4.6% 4.7% (0.1pp) Cost of Services Provided -396.7 -348.4 13.9% -381.0 4.1% -1133.2 -1027.9 10.2% % of net revenue 69.9% 71.3% (1.4pp) 69.8% 0.1pp 70.3% 70.2% 0.1pp Gross Profit 171.1 140.1 22.1% 164.8 3.8% 479.7 437.4 9.7% % Gross margin 30.1% 28.7% 1.4pp 30.2% (0.1pp) 29.7% 29.8% (0.1pp) 6
Page 7
EARNINGS RELEASE November,09,2025 Destaques do Trimestre Expenses General, Administrative and Other BRL Millions Consolidated 3Q25 3Q24 ∆ 3Q25 2Q25 ∆ 3Q25 9M25 9M24 ∆ 9M25 Personnel -41.7 -46.1 -9.6% -42.4 -1.8% -127.5 -133 -4.1% % of net revenue 7.3% 9.4% (2.1pp) 7.8% (0.5pp) 7.9% 9.1% (1.2pp) Depreciation and amortization -5.3 -5.2 2.1% -5.2 2.2% -15.8 -15.1 4.7% % of net revenue 0.9% 1.1% (0.2pp) 1.0% (0.1pp) 1,00% 1,00% - Third-party services -17.5 -13.7 27.9% -14.9 17.1% -46.4 -39.2 18.5% % of net revenue 3.1% 2.8% 0.3pp 2.7% 0.4pp 2.9% 2.7% 0.2pp Other Expenses -6.4 -7.4 -14.1% -5.7 12.2% -16.6 -17.3 -4.1% % of net revenue 1.1% 1.5% (0.4pp) 1.0% 0.1pp 1,00% 1.2% (0.2pp) General expenses and adm, -70.9 -72.4 -2.1% -68.3 3.8% -206.4 -204.6 0.8% % of net revenue 12.5% 14.8% (2.3pp) 12.5% - 12.8% 14,00% (1.2pp) Other operational rev,/exp, -2.2 68.8 -103.1% -8.6 -74.9% -18 52.8 -134.0% % of net revenue 0.4% -14.1% 14.5pp 1.6% (1.2pp) 1.1% -3.6% 4.7pp Net Operational Expenses -73 -3.6 1944.2% -76.8 -5,00% -224.3 -151.8 47.8% % of net revenue 12.9% 0.7% 12.2pp 14.1% (1.2pp) 13.9% 10.4% 3.5pp 7
Page 8
EARNINGS RELEASE November,09,2025 Destaques do Trimestre EBIT and EBITDA Operacional Result BRL Millions Consolidated 3Q25 3Q24 ∆ 3Q25 2Q25 ∆ 3Q25 9M25 9M24 ∆ 9M25 Gross Revenue 637.6 548.4 16.3% 609.9 4.5% 1807.8 1644.8 9.9% Taxes, deductions, and Disallowances -69.7 -59.9 16.4% -64.1 8.8% -194.8 -179.5 8.5% Net Revenue 567.9 488.5 16.3% 545.8 4,00% 1.613,00 1465.3 10.1% Cost of Services Provided -396.7 -348.4 13.9% -381 4.1% -1133.2 -1027.9 10.2% Net operating expenses -73 -3.6 1944.2% -76.8 -5,00% -224.3 -151.8 47.8% Asset impairment - -10.1 -100,00% - - - -754.3 -100,00% EBIT 98.1 126.4 -22.4% 88 11.5% 255.4 -468.7 -154.5% % of net revenue 17.3% 25.9% (8.6pp) 16.1% 1.2pp 15.8% -32,00% 47.8pp Reversal of contingencieson 27.8 23.9 16.1% 27.2 2,00% 82.2 70.3 17,00% EBITDA 125.9 150.3 -16.3% 115.2 9.3% 337.6 -398.4 -184.8% % of net revenue 22.2% 30.8% (8.6pp) 21.1% 1.1pp 20.9% -27.2% 48.1pp Sale of Investments / Asset impairment - 10.1 -100,00% - - - 754.3 -100,00% Pre-Operational Nova Lima - 4.3 -100,00% - - - 5.3 -100,00% Reversal of contingencies de contingências - -74 - - - - -74 - Adjusted EBITDA 125.9 90.8 38.7% 115.2 9.3% 337.6 287.2 17.6% % of net revenue 22.2% 18.6% 3.6pp 21.1% 1.1pp 20.9% 19.6% 1.3pp 8
Page 9
EARNINGS RELEASE November,09,2025 Destaques do Trimestre Net Financial Result Financial Revenue and Expense BRL Millions Consolidated 3Q25 3Q24 ∆ 3Q25 2Q25 ∆ 3Q25 9M25 9M24 ∆ 9M25 Financial Income 30.2 33.6 -10.1% 29.9 1.0% 86.7 60.2 44.0% Financial Expense -85.7 -61.3 39.9% -76.3 12.3% -227.7 -173.6 31.2% Interest on loans, financings, installments, and acquisitions -55 -39.2 40.4% -50.3 9.4% -148.9 -110.3 34.9% Lease interest -19.1 -17.1 11.8% -18.9 1.1% -56.6 -49.6 14.2% Others -11.6 -5 132.2% -7.2 61.7% -22.2 -13.7 62.8% Net Financial Result -55.5 -27.7 100.6% -46.4 19.6% -141.1 -113.4 24.4% 9
Page 10
EARNINGS RELEASE November,09,2025 Destaques do Trimestre Net Income 10 % adjusted net margin % net margin BRL Millions Consolidated 3Q25 3Q24 ∆ 3Q25 2Q25 ∆ 3Q25 9M25 9M24 ∆ 9M25 EBIT 98.1 126.4 -22.4% 88 11.5% 255.4 -468.7 -154.5% Net Financial Result -55.5 -27.7 100.6% -46.4 19.6% -141.1 -113.4 24.4% EBT 42.6 98.8 -56.9% 41.6 2.5% 114.4 -582.1 -119.6% Income Tax and Social Contribution -15.1 -34.5 -56.2% -14.5 4.4% -39.6 202.8 -119.5% Net Income 27.5 64.2 -57.2% 27.1 1.4% 74.7 -379.3 -119.7% % of net revenue 4.8% 13.2% (8.4pp) 5,00% (0.2pp) 4.6% -25.9% 30.5pp Deferred Income Tax/Social Contribution - 15.0 -100.0% - - - 51.1 -100.0% Impairment - 6.7 -100.0% - - - 497.8 -100.0% Pré-Operacional Nova Lima - 2.8 -100.0% - - - 3.5 -100.0% Reversal of contingencies - -48.8 - - - - -48.8 -100.0% Adjusted Net Income 27.5 39.9 -31.2% 27.1 1.4% 74.7 124.3 -39.9% % of net revenue 4.8% 8.2% (3.4pp) 5,00% (0.2pp) 4.6% 8.5% (3.9pp) 25 8 27 15 16 7 40 25 20 27 35 8.2% 5.1% 5.0% 6.1% 5.1% 1.7% 4.1% 4.8% 3Q24 4Q24 1Q25 2Q25 3Q25 Net Income Deferred Income Tax or Exchange Expanses
Page 11
EARNINGS RELEASE November,09,2025 Destaques do Trimestre Debt and Leverage Consolidated (BRL millions) 3Q25 3Q24 ∆ 3Q25 2Q25 ∆ 3Q25 Short-Term Debt 117 110 6.3% 99 18.1% Long-Term Debt 1,301 1,356 -4.1% 1,311 -0.8% Gross Debt¹ 1,417 1,466 -3.3% 1,410 0.5% Cash and Cash Equivalents and Financial Investments 680 756 -10.1% 638 6.5% Net Debt 738 710 3.9% 772 -4.4% EBITDA LTM! 418 563.1 -25.8% 484 -13.6% Net Debt/ EBITDA LTM 1.8 1.3 0.5 1.6 0.2 4, Does not consider transaction costs 1. According to the covenant of the Company's debenture issuances 11 710 771 781 772 738 710 726 725 690 642 45 56 82 96 3Q24 4Q24 1Q25 2Q25 3Q25 Net Debt Net Debt ex Share Buybacks and Dividends Accumulated Share Buybacks and Dividends 55 101 186 1,0154% 7% 14% 75% -100% -80% -60% -40% -20% 0% 20% 40% 60% 80% - 200 400 600 800 1,000 1,200 1,400 1,600 Less than one year Between one and three years Between three and five years More than five years 97% 3% CDI - 0,73% TJLP + 3,18%
Page 12
EARNINGS RELEASE November,09,2025 Destaques do Trimestre Cash Flow Cash and Equivalents Financial Invesments 12 614 679 654 25 134 (0) (34) (12) (24) 23 (20) 26 (14) (11) 26638 705 680 Cash Jun/25 Reconciliation of Results Δ Working Capital Interest Paid Income Tax Investment (ex- financial app.) Financial Investment Income Financing Cash Sep/25 ex-Buybacks and Exchange Share Buybacks Exchange Costs Cash Sep/25
Page 13
EARNINGS RELEASE November,09,2025 Destaques do TrimestreAppendix P&L 13 (BRL thousand) 3Q25 3Q24 2Q25 9M25 9M24 Gross Revenue 637,565 645,379 609,862 1,807,782 1,969,527 Healthcare Operator 591,490 596,398 565,214 1,673,972 1,821,978 Out-of-pocket patients 36,877 40,239 35,602 106,344 121,657 Other revenue 9,198 8,742 9,046 27,466 25,892 Taxes and Deductions (69,708) (74,558) (64,055) (194,800) (230,564) Net Revenue 567,857 570,821 545,807 1,612,982 1,738,963 Costs of services provided (396,737) (397,247) (380,982) (1,133,249) (1,197,393) Medical Supplies and drugs (154,787) (135,669) (147,156) (431,699) (417,415) Personnel (110,867) (119,559) (106,245) (321,301) (348,380) Medical services (59,719) (68,922) (57,401) (172,194) (203,626) Maintenance and conservation (23,103) (24,544) (22,945) (67,584) (77,012) Depreciation and amortization (22,429) (21,428) (21,984) (66,447) (65,149) Other costs (25,832) (27,125) (25,251) (74,024) (85,811) Gross profit 171,120 173,574 164,825 479,733 541,570 General and administrative expenses (70,863) (79,928) (68,256) (206,353) (229,534) Personnel (41,678) (50,492) (42,434) (127,534) (147,316) Depreciation and amortization (5,327) (5,816) (5,214) (15,773) (17,004) Third-party services (17,506) (15,335) (14,947) (44,428) Other expenses (6,352) (8,285) (5,661) (63,046) (20,786) Equity pickup (165) (791) (31) (1,424) (1,249) Other operating income (expenses) (1,987) 70,945 (8,542) (16,541) (697,282) Impairment of assets- CPC 31 - (10,122) - - - Earnings before financial income and expenses 98,105 153,678 87,996 255,415 (386,495) Financial revenue 30,202 34,106 29,909 86,654 61,952 Financial expenses (85,706) (65,963) (76,328) (227,717) (189,723) Net financial result (55,504) (31,857) (46,419) (141,063) (127,771) Earnings before income tax and social contribution 42,601 121,821 41,577 114,352 (514,266) Income Tax and Social Contribution (15,119) (41,290) (14,486) (39,606) 182,216 Net Income / (Loss) 27,482 80,531 27,091 74,746 (332,050) Deferred Income tax (goodwill) - 15,000 - - 51,116 Divestment of assets / Impairment of assets - 6,681 - - 497,815 Nova Lima preoperational - 2,824 - - 3,475 Contingencies reversal - (48,824) - - (48,824) Adjusted net income 27,482 56,212 27,091 74,746 171,532 (BRL thousand) 3Q25 3Q24 2Q25 9M25 9M24 EBIT 98,105 153,677 87,996 255,415 (386,495) Depreciation and amortization 27,756 27,244 27,198 82,220 82,153 EBITDA 125,861 180,921 115,194 337,635 (304,342) Nova Lima preoperational - 4,278 - - 5,265 Divestment of assets / Impairment of assets - 10,122 - - 754,264 Contingencies reversal - (73,975) - - (73,975) Adjusted EBITDA 125,861 121,346 115,194 337,635 381,212
Page 14
EARNINGS RELEASE November,09,2025 Destaques do TrimestreAppendix Balance Sheet 14 (BRL thousand) 09/30/2025 09/30/2024 Asset Current Cash and Cash Equivalents 654,027 704,454 Financial Investments 25,516 51,460 Accounts receivable 742,217 653,957 Inventories 64,261 48,183 Construction Reimbursement 42,248 40,125 Other current assets 34,198 45,777 Assets held for sale - - Total current assets 1,562,929 1,544,534 Non-current Construction Reimbursement 266,937 295,099 Judicial deposits 57,390 50.192 Deferred taxes 231,401 231,274 Investments 11,837 15,773 Right of use 675,117 662,899 Fixed Assets 814,564 835,309 Intangible Assets 730,981 728,753 Other non-current assets 49,781 49,766 Total non-current assets 2,838,008 2,869,065 Total Assets 4,400,937 4,413,599 Liabilities Current Suppliers 143,809 116,705 Loans and financingCP 89,945 99,719 Derivatives 2,951 984 LeasingCP 71,533 65,654 Salaries & social security contribution 90,076 82,570 Taxes and contributions payable 39,939 18,890 Installment payment of taxesCP 463 6,960 Accounts payable of company acquisition 26,888 37,236 Redemption liability 58,369 - Other current liabilities 11,019 8,861 Liability held for sale - - Total current liabilities 534,992 437,579 Non-current Loans and financingLP 1,300,903 1,356,412 Derivatives 23,611 8,934 LeasingLP 708,009 676,120 Redemption liability - 80,778 Installment payment of taxesLP 541 930 Deferred taxes liabilities 77,019 78,093 Accounts payable of company acquisition 141,460 156,223 Provision for contingencies 113,919 105,131 Other non-current liabilities 7,801 12,058 Total non-current liabilities 2,373,263 2,474,679 Equity Capital Capital 1,301,019 1,301,019 Capital reserves 202,951 243,467 Income reserves 41,537 49,605 (-) Treasury stocks (2,423) (30,119) Equity valuation adjustment (80,269) (90,705) Total equity attributable to the Company’s shareholder 1,462,815 1,473,267 Share of noncontrolling shareholders 29,867 28,074 Total Shareholders’ equity 1,492,682 1,501,341 Total Liabilities 4,400,937 4,413,599
Page 15
EARNINGS RELEASE November,09,2025 Destaques do TrimestreAppendix Cash Flow 15 (BRL thousand) 09/30/2025 09/30/2024 Cash flow from operating activities Net profit for the period 74,746 (332,050) Adjustments to reconcile net income to cash from operations Depreciation and amortization 82,220 82,153 Write-off of fixed and intangible assets 3,180 3,062 Establishment (reversal) of allowance for doubtful accounts 12,045 20,024 Establishment (reversal) of provision for disallowances 13,317 28,398 Establishment (reversal) of provision and restatement for contingencies 7,543 (85,023) Share-Based Payment provision 3,439 6,552 Equity pickup gains 1,424 1,249 Derivative Gains 6,153 (581) Income from financial investiments (62,659) (22,276) Net financial expenses 191,846 159,973 Establishment of Installment payment of taxes - 938 Loss of impairment of assets - 754,264 Provision for income tax and social contribution - current & deferred (2,781) (200,670) 330,473 416,013 Variations in Operating Assets and Liabilities Accounts Receivable (106,995) (146,443) Inventories (14,504) (505) Other Assets 13,900 2,816 Judicial Deposits (6,213) (3,358) Suppliers 14,005 (5,796) Salaries and social security contributions 32,781 25,640 Taxes and contributions payable 39,181 12,196 Tax installments (5,614) (5,150) Variations in Operating Assets from alienated assets - (39,995) Other liabilities 1,190 (1,293) (32,269) (161,888) Income tax and social contributions paid (23,060) (19,595) Interest paid (137,468) (85,578) Net cash generated by operating activities 137,676 148,952 Cash Flow of Investment activities Acquisition of fixed assets (30,638) (167,224) Acquisition of intangible assets (9,986) (8,422) Developments with construction to be deployed - (11,801) A Capital Injection into the acquired units - (95) Investment acquisition (35,179) (29,156) Disposal of investments - 388,720 Financial Investiments made, net redemptions 89,878 52,603 Net cash generate (used) in investment activities 14,075 224,625 Cash flow from financing activities Loans and financing 700,000 206,893 Payments of loans and financing (747,420) (32,261) Lease payments (17,892) (28,563) Derivative settlement (4,711) (237) Treasury stocks (35,509) (13,839) Dividends paid (14,773) (28,418) Net cash generated (used) in financing activities (120,305) 103,575 INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 31,446 477,152 Cash and cash equivalents at the beginning of the period 622,581 227,302 Cash and cash equivalents at the end of the period 654,027 704,454 INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 31,446 477,152
Page 16
EARNINGS RELEASE November,10,2025 Glossary and Other Information 16